Sarepta Therapeutics Inc (SRPT)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 82.76% | 85.39% | 87.71% | 88.18% | 87.91% | 87.60% | 86.06% | 85.29% | 85.00% | 83.91% | 85.10% | 86.14% | 86.17% | 86.41% | 86.79% | 87.25% | 88.26% | 88.58% | 87.88% | 85.98% |
| Operating profit margin | 11.47% | 4.94% | 2.52% | -6.76% | -21.54% | -36.13% | -50.81% | -60.20% | -57.47% | -61.09% | -52.48% | -51.55% | -65.50% | -81.26% | -104.52% | -104.30% | -104.46% | -125.97% | -135.54% | -183.36% |
| Pretax margin | 13.71% | 7.89% | 4.13% | 2.43% | -41.83% | -59.89% | -88.20% | -112.59% | -73.95% | -81.11% | -60.11% | -46.45% | -59.69% | -75.21% | -105.66% | -122.63% | -102.40% | -121.11% | -117.57% | -160.66% |
| Net profit margin | 12.37% | 7.43% | 3.14% | 1.20% | -43.11% | -62.52% | -90.46% | -114.30% | -75.40% | -81.76% | -60.66% | -46.56% | -59.66% | -75.30% | -105.73% | -122.77% | -102.60% | -121.30% | -117.80% | -160.96% |
Sarepta Therapeutics Inc has shown a fluctuating trend in its profitability ratios over the years. The gross profit margin has remained relatively high, ranging from 85% to 88% during the period under review. This indicates that the company has been able to effectively control its production costs and generate a healthy gross profit from its operations.
On the other hand, the operating profit margin and pretax margin have fluctuated significantly, with both ratios showing negative values in the initial years but gradually improving to positive figures by the end of the period. This suggests that the company has been able to better manage its operating expenses and generate higher profits before and after tax over time.
Similarly, the net profit margin, which reflects the company's bottom-line profitability, has also shown improvement from negative values to positive percentages. This indicates that Sarepta Therapeutics Inc has been able to enhance its overall profitability through better cost management and revenue generation strategies.
Overall, while the company has faced challenges in terms of profitability in the past, the improving trend in its profitability ratios reflects a positive outlook for Sarepta Therapeutics Inc's financial performance.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.50% | 2.25% | 1.11% | -2.94% | -8.20% | -12.84% | -16.31% | -19.20% | -17.14% | -16.96% | -14.62% | -12.92% | -14.60% | -19.71% | -22.73% | -21.63% | -18.90% | -22.43% | -21.16% | -25.35% |
| Return on assets (ROA) | 5.94% | 3.38% | 1.38% | 0.52% | -16.42% | -22.22% | -29.04% | -36.45% | -22.49% | -22.69% | -16.91% | -11.67% | -13.30% | -18.26% | -23.00% | -25.45% | -18.57% | -21.60% | -18.40% | -22.25% |
| Return on total capital | 17.02% | 10.60% | 5.10% | 4.81% | -58.85% | -84.51% | -114.92% | -147.98% | -165.40% | -150.39% | -60.32% | -34.08% | -38.30% | -88.44% | -117.06% | -119.58% | -64.34% | -61.78% | -46.52% | -53.77% |
| Return on equity (ROE) | 15.40% | 9.98% | 4.39% | 1.76% | -62.37% | -90.39% | -122.43% | -156.47% | -182.75% | -166.24% | -69.74% | -41.61% | -45.13% | -103.53% | -130.79% | -131.46% | -72.74% | -67.32% | -50.85% | -57.29% |
Sarepta Therapeutics Inc's profitability ratios show a fluctuating trend over the periods analyzed.
- Operating return on assets (Operating ROA) started at a negative 25.35% in March 2020, gradually improved to -2.94% by March 2024.
- Return on assets (ROA) also began in negative territory at -22.25% in March 2020, showing a recovery to 5.50% by December 2024.
- Return on total capital, indicating the company's efficiency in generating profits from its total capital, had a substantial negative figure of -53.77% in March 2020, but reached 17.02% by December 2024.
- Return on equity (ROE), reflecting the returns generated for shareholders, started at a low of -57.29% in March 2020, with a positive upturn to 15.40% by December 2024.
Overall, there is a noticeable improvement in profitability ratios from negative values in early periods to positive figures by the end of the analyzed period. This indicates an enhancement in the company's ability to generate profits relative to its assets, capital, and equity over time.